Your Article Summary
See Latest ArticlesSmall-cell prostate carcinoma: A retrospective analysis of five newly reported cases
Indian Journal of Urology, 06/26/09
Brownback KR et al. - The PSA levels varied greatly, with two patients possessing markedly elevated levels and the remaining patients with normal levels. Approximately 3/5 patients developed liver metastases, 2/5 patients had bone metastases, and 1/5 patients developed carcinomatous meningitis. Of the four patients who expired, the median survival time after diagnosis of SCC was 3.6 months (0.5-12 months).
Related Articles
Epac inhibits migration and proliferation of human prostate carcinoma cells
British Journal of Cancer, 11/20/09
Relevance Score: 68%
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/30/09
Relevance Score: 67%
Prostate carcinoma, presenting with a solitary osteolytic bone lesion to the right hip
Radiology Case Reports, 11/23/09
Relevance Score: 67%
Testosterone therapy and prostate carcinoma
Current Urology Reports, 11/17/09
Relevance Score: 66%
A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate
International Urology and Nephrology, 11/04/09
Relevance Score: 66%
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09
Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature
European Urology, 12/04/09